🟢 Adaptive Biotechnologies is trading 6.4% up in pre-market with no clear catalyst identified

Adaptive Biotechnologies is trading at $25.99, up 6.4%, with no clear catalyst identified.

• The stock rose from its September 9 close of $24.42; no fresh company-specific announcement, earnings release, or regulatory catalyst was identified for September 10, 2026.
• Next announced event is a Morgan Stanley healthcare conference fireside chat on September 15, 2026, too distant to explain the pre-market move confidently.
• Major U.S. indices are lower, so broader sentiment does not clearly explain the move.